December 26, 2012 — Flexible Stenting Solutions Inc. (FSS) announced it gained CE mark in the European Union for its 6 French Reconstrainable FlexStent Femoropopliteal self-expanding stent system. FSS is a developer of next-generation peripheral, neurovascular and biliary stents. This new device combines advanced FlexStent technology with unique reconstrainable stent delivery technology.
Reconstrainability enables the physician to fully recapture, then reposition, a partially deployed stent. Based on ongoing market research and physician feedback, FSS believes reconstrainability will be a powerful tool for optimizing stent placement in challenging vascular anatomies, thereby enhancing overall patient safety. The Reconstrainable FlexStent Femoropopliteal self-expanding stent system is indicated for the treatment of symptomatic atherosclerotic disease of the femoropopliteal arteries. Stent and system sizes include stent diameters of 5, 6, 7 and 8 mm in lengths of 30 to 200 mm, with delivery system lengths of 80 cm and 120 cm, as originally CE mark authorized with the standard delivery system.
FSS intends to apply the novel reconstrainable delivery technology across its platform of current and future stent products. With the easy-to-use reconstrainable delivery system, the complete FlexStent family of stents can be delivered with the same simplicity and low force demonstrated by the standard delivery system. Recapture and secondary deployment of the stent in the reconstrainable system are both accomplished with equal ease and simplicity.
For more information: www.flexiblestent.com
November 08, 2024 
